Cho Joon Hyun, Bilal Mohammad, Kim Min Cheol, Cohen Jonah
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Center for Advanced Endoscopy, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Clin Endosc. 2021 Jan;54(1):9-16. doi: 10.5946/ce.2020.302. Epub 2021 Jan 29.
Obesity is becoming increasingly prevalent worldwide, and its metabolic sequelae lead to a significant burden on healthcare resources. Options for the management of obesity include lifestyle modification, pharmacological treatment, surgery, and endoscopic bariatric therapies (EBTs). Among these, EBTs are more effective than diet and lifestyle modification and are less invasive than bariatric surgery. In recent years, there have been significant advances in technologies pertaining to EBTs. Of all the available EBTs, there is a significant amount of clinical experience and published data regarding intragastric balloons (IGBs) because of their comparatively long development period. Currently, the United States Food and Drug Administration (FDA) has approved three IGBs, including Orbera (Apollo Endosurgery, Austin, TX, USA), ReShape Duo (ReShape Medical, San Clemente, CA, USA), and Obalon (Obalon Therapeutics, Carlsbad, CA, USA). The aim of this review is to summarize the available literature on the efficacy of IGBs in weight loss and their impact on obesity-related metabolic diseases.
肥胖在全球范围内正变得越来越普遍，其代谢后遗症给医疗资源带来了沉重负担。肥胖管理的选择包括生活方式改变、药物治疗、手术以及内镜减重治疗（EBTs）。其中，EBTs比饮食和生活方式改变更有效，且比减重手术侵入性更小。近年来，与EBTs相关的技术取得了重大进展。在所有可用的EBTs中，由于胃内球囊（IGBs）的研发周期相对较长，因此有大量的临床经验和已发表的数据。目前，美国食品药品监督管理局（FDA）已批准了三种IGBs，包括奥贝拉（Orbera，美国德克萨斯州奥斯汀市阿波罗内镜手术公司）、重塑双子星（ReShape Duo，美国加利福尼亚州圣克莱门特市重塑医疗公司）和奥巴隆（Obalon，美国加利福尼亚州卡尔斯巴德市奥巴隆治疗公司）。本综述的目的是总结关于IGBs在减肥方面的疗效及其对肥胖相关代谢疾病影响的现有文献。
